CytoSorbents Corporation (CTSO)

[techxen]

New study Post-Cardiac Arrest Syndrome (CATCH)

Another new study staring in June. This study is being conducted out of Centre Hospitalier Universitaire Vaudois one of 5 university hospitals in Switzerland, 40 patients running through 2020.

Post Cardiac Arrest Syndrome (PCAS) describes the spectrum of organ dysfunction. The four key components of PCAS are:
- Post-cardiac arrest brain injury
- Post-cardiac arrest myocardial dysfunction
- Systemic ischaemia/reperfusion response
- Persistent precipitating pathology

In the US, in-hospital mortality rates after transfer to hospital are 60–70% for PCAS. The prognosis for postcardiac arrest patients remains very bleak, not only because of anoxic-ischemic neurological damage, but also because of the "postcardiac arrest syndrome," a phenomenon often severe enough to cause death before any neurological evaluation. This syndrome includes all clinical and biological manifestations related to the phenomenon of global ischemia-reperfusion triggered by cardiac arrest and return of spontaneous circulation. The main component of the postcardiac arrest syndrome is an early but severe cardiocirculatory dysfunction that may lead to multiple organ failure and death. Out-of-hospital cardiac arrest (OHCA) is a common initial presentation of cardiovascular disease, affecting up to 325 000 people in the United States each year.

I would imagine that the length of this trial and the small number of patients they are recruiting is indicative of the complexity of this type of study. There are numerous factors in the "chain of survival" from the procedures performed by the EMT's in the field to the hospital staff.

https://clinicaltrials.gov/ct2/show/NCT03523039?lupd_s=04%2F18%2F2018&lupd_d=30